Study design
BLIND
This was a randomized, double blind, placebo controlled, 2-part single and multiple ascending dose study. The objectives were to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of OCS-05 in healthy subjects. Inclusion criteria included healthy (as judged by the Investigator; no clinically significant abnormalities) male and female (non-pregnant, non-lactating) subjects between 18 and 55 years of age, with a body weight of ≥ 50.0 kg and ≤ 100 kg and body mass index (BMI) of 18 to 32 kg/m